redosable-gene-therapy
(2)
Krystal Biotech, Inc.
Krystal Biotech is a Pittsburgh-based commercial-stage biotechnology company that pioneered redosable, off-the-shelf gene therapy delivered directly to the body. Its lead product VYJUVEK became the first FDA-approved topical and redosable gene therapy in 2023, treating the rare skin disease dystrophic epidermolysis bullosa. Built on a proprietary HSV-1 vector platform (STAR-D), the company runs its own GMP manufacturing and is extending the same delivery technology into respiratory disease, oncology, ophthalmology and aesthetics.
Tuyen Ong
Tuyen Ong is a physician-turned-biotech executive who spent four years as CEO of Ring Therapeutics, the Flagship Pioneering company trying to turn anelloviruses - harmless viruses that already live in nearly everyone - into a redosable delivery system for genetic medicines. Trained as an ophthalmologist at University College London with an MBA from NYU Stern, he built his career on gene therapy for rare eye disease at Nightstar, Biogen, PTC, Bausch & Lomb and Pfizer before betting on a virus most scientists had written off as biological junk. In 2025 he co-founded PharmasMarket, a drug-development consultancy.